Document is current
Any future updates will be listed below
-
Authors
Preet, Ranjan https://orcid.org/0000-0001-6117-2701
Islam, Md Atiqul
Shim, Jiyoung https://orcid.org/0000-0001-6973-9530
Rajendran, Ganeshkumar
Mitra, Amrita https://orcid.org/0000-0002-1936-2189
Vishwakarma, Vikalp
Kutz, Caleb
Choudhury, Sonali
Pathak, Harsh
Dai, Qun
Sun, Weijing https://orcid.org/0000-0001-6549-9605
Madan, Rashna
Zhong, Cuncong
Markiewicz, Mary A. https://orcid.org/0000-0001-5685-8573
Zhang, Jun https://orcid.org/0000-0001-7886-6187
-
Funding
Funding for this research was provided by:
Startup funds and E3DT grant from the University of Kansas Medical Center
- License Information
-
More Information
Article History
Received: 22 October 2023
Accepted: 24 March 2025
First Online: 12 April 2025
Competing interests
: JZ has served as a scientific advisor/consultant for: AstraZeneca, Bayer, Biodesix, BMS, Cardinal Health, Daiichi Sankyo, Fosun, Hengrui, Eli Lilly, Mirati, Nexus Health, Novartis, Novocure, Regeneron, Sanofi and Takeda. He is on the speakers’ bureau for AstraZeneca, Regeneron, Sanofi and MJH Life Sciences. He has also received research funding or support from Abbvie, AstraZeneca, BeiGene, Biodesix, BridgeBio, BMS, Champions Oncology, Eli Lilly, Genentech, Hengrui, InnoCare Pharma, Janssen, Kahr Medical, Merck, Mirati, Nilogen and Novartis. In addition, he is the inventor of a patent application submitted by KUMC with the Application Serial No 63/705,859, based on the findings from this project. MAM has served as a paid consultant for Johnson & Johnson and Design-Zyme and has received research funding from Targovax. The remaining authors declare no competing interests.
